Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Garvey’s career spans decades of influential work, shaping national guidelines for obesity and diabetes treatment.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated with ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Wegovy (semaglutide) is a prescription drug used for weight management and heart disease related to obesity. Wegovy can cause side effects that range from mild to serious. Examples include ...